FOLH1 and neoplasm: 177Lu-PSMA-617 (Lu-PSMA-617) radiolabeled radioligand therapy (RLT) binds to PSMA-expressing tumor cells, delivering targeted radiation and leaving minimal damage to healthy tissues [11,12,13,14,15].